December 10, 2020 5:48pm
A scorecard of 34 earnings releases and 1 acquisition of 35 covered companies
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
|
COMPANY |
SYMBOL | NET INCOME | Q3/20 LOSS | Q3/20 LPS | Q2/20 CASH | RUNWAY |
|---|---|---|---|---|---|---|
|
Chinook Therapeutics formerly, Aduro Biotech (ADRO) |
KDNY | –$14.5 M | –$0.90 | $74.31 M | 2022 | |
|
Alnylam Pharmaceuticals |
ALNY | –$253.2 M | –$2.18 |
$1.83 Billion |
N/A | |
| Applied Genetic Technologies | AGTC |
–$15.4 M |
–$0.60 |
$66.6 M | 04/21 | |
| Athersys, Inc. | ATHX | –$22.5 M | –$0.11 |
$61.7 M |
Q4/21 | |
|
Adverum Biotechnologies |
ADVM | –$27.8 M | –$0.31 |
$454.5 M |
mid-2022 | |
| AxoGen | AXGN | –$1.5 M | –$0.04 | $106.7 M | 2022 | |
|
Bellicum Pharmaceuticals |
BLCM |
|
–$900 K | –$0.18 | $54.6 M | Q2/22 |
|
BioLife Solutions |
BLFS |
|
–$1.1 M | –$0.04 |
$109 M |
2024 |
| Biostage | BSTG | –$700 K | –$0.07 |
$2 M |
Q1/21 | |
| bluebird bio | BLUE | -$194.7 M | –$2.94 | $1.44 B | 2023 | |
| Brainstorm Cell Therapeutics | BCLI | –$4.49 M | –$0.70 |
$28.8 M |
2021 | |
|
Caladrius Biosciences. |
CLBS | –$5.3 M | –$0.29 |
$40.3 M |
Q2/21 |
|
| Cellectis SA | CLLS |
|
–$30 M | –$0.71 | $308 M | 2022 |
|
CRISPR Therapeutics |
CRSP | –$92.4 M | –$1.32 | $1.4 B | 2023 | |
|
Editas Medicine |
EDIT |
+7.8 M or +$0.12 |
$541.3 M | 2023 | ||
|
Fate Therapeutics |
FATE | –$58.6 M | –$0.68 |
$502 M |
2022 | |
|
Global Blood Therapeutics |
GBT | –$59.9 M | –$0.97 | $535.2 M | 2024 | |
|
Homology Medicine |
FIXX | –$28.2 M | –$0.62 | $178 M | 2022 | |
|
Intellia Therapeutics |
NTLA | –$27.8 M | –$0.47 | $407.9 M | 2022 | |
|
Precigen formerly Intrexon |
PGEN | –$29.5 M | –$0.18 | $113.1 M | 2021 | |
|
Ionis Pharmaceuticals |
IONS |
|
–$14.5 M | –$7.00 | $2.35 B | N/A |
| Mesoblast | MESO |
–$X M |
–$X |
$X M |
||
| MiMedx Group |
MDXG |
|
–$19.4 M |
–$0.48 |
$109.6 M |
Q2/2022 |
|
Pluristem Therapeutics |
PSTI | –$X M | –$X |
$59 M |
2021 | |
|
ReNeuron Group |
RENE.L | |||||
| Regenxbio | RGNX | –$8.8 M | –$0.24 | $289.8 M | mid-22 | |
|
Sage Therapeutics |
SAGE | –$105.7 M | –$2.03 | $671 M | 2022 | |
|
Sangamo Biosciences |
SGMO | –$1.6 M | –$0.01 |
$694.5 M |
2022 | |
|
Solid Biosciences |
SLDB |
–$21.2 M |
–$0.44 | $24.8 M | 2H/21 | |
| StemlineTherapeutics | STML |
Acquired by Menarini, an Italian pharma |
||||
| Ultragenyx | RARE | -$68.8 M | -$1.13 | $7.65 M | N/A | |
| uniQure N.V. | QURE | –$53.8 M | –$1.21 | $279.5 M | 2h/24 | |
| Verastem | VSTM | –$1.31 M | –$0.08 |
$205.7 M |
2024 | |
| Vericel | VCEL | –$3.6 M | –$0.08 | $85.5 M | 2022 | |
|
Voyager Therapeutics |
VYGR |
+$85.6 M or +2.27 |
$200 M | mid-2022 |
